Respiration

 

Bronchoalveolar Lavage in Chronic Eosinophilic Pneumonia

Analysis of Six Cases in Comparison with Other Interstitial Lung Diseases

Pesci A.a · Bertorelli G.a · Manganelli P.b · Mori P.A.a · Strinati F.a · Marangio E.a · Olivieri D.a

Author affiliations

aIstituto di Clinica delle Malattie dell’Apparato Respiratorio e bCattedra di Reumatologia, Università degli Studi di Parma, Italia

Related Articles for ""

Respiration 1988;54:16–22

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: January 20, 2009
Issue release date: 1988

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: https://www.karger.com/RES

Abstract

We describe 6 patients with chronic eosinophilic pneumonia (CEP) investigated clinically and by bronchoalveolar lavage (BAL). The BAL findings of these 6 patients were compared with those of 293 patients with other interstitial lung diseases (ILD): 184 with sarcoidosis, 63 with hypersensitivity pneumonitis, 46 with idiopathic pulmonary fibrosis (IPF). In patients with CEP, BAL analysis was characterized by a markedly increased number of eosinophils (mean ± 1 SD: 54.2 ± 26.4 of effector cells; in control subjects, eosinophils were < 1% of effector cells). In patients with other ILD, BAL fluid analysis showed a significant increase in the percentage of eosinophils only in the group of IPF, but in IPF the increased number of eosinophils is linked with a significant increase in the percentage of neutrophils. These findings indicate that besides the classic patterns of lymphocytosis or polymorphonuclear leukocytosis, a predominantly eosinophilic pattern may also be present in the BAL fluid. Moreover, BAL may contribute to understanding the pathogenesis of lung tissue damage in CEP.

© 1988 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: January 20, 2009
Issue release date: 1988

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: https://www.karger.com/RES


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP